Amarin Corp Plc (AMRN)

[Chris2125]

June Investor Presentation

Appealing to U.S. Court of Appeals for the Federal Circuit
? Good arguments on appeal
? Proceeding on an expedited schedule
– Expected completion of briefing in June 2020
– Oral argument (possibly telephonic) expected in Q3/Q4 2020
– Ruling expected in Q4 2020 or Q1 2021: WHAT HAPPENED TO POSSIBLY first week of September ruling???

Commercialization opportunities
? Leading medical societies in Europe, ESC and EAS, have already added icosapent ethyl (US brand name
VASCEPA) to their medical guidelines
? Seeking to become first and only drug in EU with this labeling for this large unmet medical need
? Pricing review underway based on cardiovascular risk reduction with unprecedented outcomes study data from
REDUCE-IT (not for TG lowering indication for which VASCEPA launched in U.S.)
? Evaluating whether to launch in EU directly, via a partner or in a hybrid form with decision targeted for Q3 2020: IS EUROPE BEING SLOW PLAYED TO HAVE A US COURT RULING FIRST BEFORE MAKING THIS DECISION?


https://investor.amarincorp.com/static-files/a04b0ba7-e5a1-4a8b-93f3-3a21734a7c2a